

Frank Follmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6402479/publications.pdf>

Version: 2024-02-01

40
papers

2,222
citations

318942

23
h-index

325983

40
g-index

41
all docs

41
docs citations

41
times ranked

2825
citing authors

#	ARTICLE	IF	CITATIONS
1	A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars. <i>Npj Vaccines</i> , 2021, 6, 58.	2.9	15
2	Chitin-derived polymer deacetylation regulates mitochondrial reactive oxygen species dependent cGAS-STING and NLRP3 inflammasome activation. <i>Biomaterials</i> , 2021, 275, 120961.	5.7	20
3	Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With Chlamydia trachomatis. <i>Frontiers in Immunology</i> , 2021, 12, 790463.	2.2	11
4	Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming. <i>Vaccine</i> , 2020, 38, 635-643.	1.7	2
5	Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge. <i>Npj Vaccines</i> , 2020, 5, 7.	2.9	26
6	Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1091-1100.	4.6	120
7	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019, 304, 65-74.	4.8	30
8	Genital Infiltrations of CD4+ and CD8+ T Lymphocytes, IgA+ and IgG+ Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01. <i>Frontiers in Microbiology</i> , 2019, 10, 197.	1.5	7
9	Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein-Based Fusion Antigen CTH522 Into Protein Nanoparticles. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1690-1700.	1.6	3
10	A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against <i>Chlamydia trachomatis</i> . <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 525-532.	1.1	14
11	A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522. <i>Journal of Controlled Release</i> , 2018, 271, 88-97.	4.8	48
12	The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. <i>Vaccine</i> , 2017, 35, 1705-1711.	1.7	21
13	Intrauterine inoculation of minipigs with Chlamydia trachomatis during diestrus establishes a longer lasting infection compared to vaginal inoculation during estrus. <i>Microbes and Infection</i> , 2017, 19, 334-342.	1.0	12
14	Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract. <i>Frontiers in Immunology</i> , 2017, 8, 569.	2.2	42
15	Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis. <i>Frontiers in Immunology</i> , 2017, 8, 1652.	2.2	30
16	Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization. <i>PLoS ONE</i> , 2017, 12, e0176401.	1.1	30
17	A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance. <i>Frontiers in Immunology</i> , 2016, 7, 162.	2.2	24
18	Genital tract lesions in sexually mature Göttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D. <i>BMC Veterinary Research</i> , 2016, 12, 200.	0.7	8

#	ARTICLE	IF	CITATIONS
19	Characterization of cytological changes, IgA, IgG and IL-8 levels and pH value in the vagina of prepubertal and sexually mature Ellegaard GÅttingen minipigs during an estrous cycle. <i>Developmental and Comparative Immunology</i> , 2016, 59, 57-62.	1.0	10
20	Quantitative Protein Profiling of <i>Chlamydia trachomatis</i> Growth Forms Reveals Defense Strategies Against Tryptophan Starvation. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3540-3550.	2.5	34
21	Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. <i>Scientific Reports</i> , 2016, 6, 19570.	1.6	205
22	A multi- α subunit <i>Chlamydia</i> vaccine inducing neutralizing antibodies and strong IFN γ CMI responses protects against a genital infection in minipigs. <i>Immunology and Cell Biology</i> , 2016, 94, 185-195.	1.0	48
23	Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with <i>Chlamydia trachomatis</i> . <i>Frontiers in Immunology</i> , 2015, 6, 628.	2.2	58
24	Intramuscular Immunisation with Chlamydial Proteins Induces <i>Chlamydia trachomatis</i> Specific Ocular Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141209.	1.1	20
25	Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. <i>Journal of Controlled Release</i> , 2015, 210, 48-57.	4.8	76
26	Protection Against <i>Chlamydia trachomatis</i> Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. <i>Journal of Infectious Diseases</i> , 2015, 212, 978-989.	1.9	99
27	A review of the human vs. porcine female genital tract and associated immune system in the perspective of using minipigs as a model of human genital <i>Chlamydia</i> infection. <i>Veterinary Research</i> , 2015, 46, 116.	1.1	65
28	An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. <i>Microbial Cell Factories</i> , 2014, 13, 162.	1.9	38
29	Characterization of protective immune responses promoted by human antigen targets in a urogenital <i>Chlamydia trachomatis</i> mouse model. <i>Vaccine</i> , 2014, 32, 685-692.	1.7	13
30	Decoration of Outer Membrane Vesicles with Multiple Antigens by Using an Autotransporter Approach. <i>Applied and Environmental Microbiology</i> , 2014, 80, 5854-5865.	1.4	95
31	Protection against <i>Chlamydia</i> Promoted by a Subunit Vaccine (CTH1) Compared with a Primary Intranasal Infection in a Mouse Genital Challenge Model. <i>PLoS ONE</i> , 2010, 5, e10768.	1.1	54
32	Novel Generation Mycobacterial Adjuvant Based on Liposome-Encapsulated Monomycoloyl Glycerol from <i>Mycobacterium bovis</i> Bacillus Calmette-Guérin. <i>Journal of Immunology</i> , 2009, 183, 2294-2302.	0.4	39
33	Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements. <i>PLoS ONE</i> , 2008, 3, e3116.	1.1	262
34	Liposome Delivery of <i>Chlamydia muridarum</i> Major Outer Membrane Protein Primes a Th1 Response That Protects against Genital Chlamydial Infection in a Mouse Model. <i>Journal of Infectious Diseases</i> , 2008, 198, 758-767.	1.9	78
35	Antigenic Profiling of a <i>Chlamydia trachomatis</i> Gene Expression Library. <i>Journal of Infectious Diseases</i> , 2008, 197, 897-905.	1.9	36
36	Identification of Human T Cell Targets Recognized during <i>Chlamydia trachomatis</i> Genital Infection. <i>Journal of Infectious Diseases</i> , 2007, 196, 1546-1552.	1.9	19

#	ARTICLE	IF	CITATIONS
37	Identification of CT521 as a Frequent Target of Th1 Cells in Patients with Urogenital Chlamydia trachomatis Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 1258-1266.	1.9	22
38	Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 65-69.	2.5	297
39	A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. <i>Vaccine</i> , 2004, 22, 1188-1198.	1.7	82
40	PPE Protein (Rv3873) from DNA Segment RD1 of Mycobacterium tuberculosis : Strong Recognition of Both Specific T-Cell Epitopes and Epitopes Conserved within the PPE Family. <i>Infection and Immunity</i> , 2003, 71, 6116-6123.	1.0	109